KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026)

Amneal Pharmaceuticals has reported Cash from Financing Activities over the past 9 years, most recently at -$10.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 83.47% year-over-year to -$10.1 million; the TTM value through Dec 2025 reached -$31.5 million, up 85.11%, while the annual FY2025 figure was -$31.5 million, 85.11% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$10.1 million at Amneal Pharmaceuticals, down from $59.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $59.4 million in Q3 2025 and troughed at -$100.8 million in Q4 2023.
  • A 5-year average of -$35.0 million and a median of -$36.6 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: crashed 354.87% in 2023 and later surged 164.37% in 2025.
  • Year by year, Cash from Financing Activities stood at -$30.4 million in 2021, then rose by 26.96% to -$22.2 million in 2022, then crashed by 354.87% to -$100.8 million in 2023, then skyrocketed by 39.3% to -$61.2 million in 2024, then skyrocketed by 83.47% to -$10.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AMRX at -$10.1 million in Q4 2025, $59.4 million in Q3 2025, and -$41.7 million in Q2 2025.